Study guide

1.3 Clinical Decision-Making & MCQ Strategy

FEBU Part 1 Written European Board of Urology

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Exam Strategy

1.1 FEBU Part 1 Examination Structure & Logistics 1.2 EAU Guidelines Framework & Standard Setting 1.3 Clinical Decision-Making & MCQ Strategy 1.4 Professionalism and Safe Practice

2 Chapter 2: Genitourinary Anatomy & Renal Physiology

2.1 Upper Tract Anatomy & Retroperitoneal Relationships 2.2 Lower Urinary Tract Anatomy & Neuroanatomy 2.3 Renal Physiology, Glomerular Filtration & Acid-Base Balance

3 Chapter 3: Urological Pharmacology & Diagnostic Imaging

3.1 Lower Urinary Tract Pharmacotherapy 3.2 Antimicrobial Stewardship & Perioperative Care 3.3 Diagnostic Modalities: Ultrasound, CT, mpMRI & Nuclear Medicine

4 Chapter 4: Prostate Cancer: Diagnosis & Risk Stratification

4.1 PSA Kinetics, Biomarkers & Risk Assessment 4.2 Multiparametric MRI (PI-RADS) & Biopsy Strategies 4.3 Histopathological Grading (ISUP Gleason) & Staging

5 Chapter 5: Prostate Cancer: Localized & Advanced Management

5.1 Active Surveillance & Watchful Waiting 5.2 Radical Prostatectomy & Radiation Therapy 5.3 Biochemical Recurrence & Salvage Therapies 5.4 Metastatic & Castration-Resistant Prostate Cancer (CRPC)

6 Chapter 6: Bladder Cancer: Non-Muscle Invasive (NMIBC)

6.1 TURBT Technique & Pathological Staging 6.2 EAU Risk Stratification for NMIBC 6.3 Intravesical Chemotherapy & BCG Immunotherapy

7 Chapter 7: Muscle-Invasive Bladder Cancer & Upper Tract Urothelial Carcinoma

7.1 Muscle-Invasive Bladder Cancer (MIBC) Staging & Neoadjuvant Therapy 7.2 Radical Cystectomy & Urinary Diversion 7.3 Upper Tract Urothelial Carcinoma (UTUC)

8 Chapter 8: Renal Cell Carcinoma & Adrenal Neoplasms

8.1 Histological Subtypes, Genetics & Staging of RCC 8.2 Localized RCC: Nephron-Sparing Surgery & Radical Nephrectomy 8.3 Metastatic RCC & Targeted / Immunotherapy Regimens 8.4 Adrenal Masses & Incidentalomas

9 Chapter 9: Testicular Germ Cell Tumours & Penile Cancer

9.1 Testicular Cancer Diagnosis, Staging & Tumour Markers 9.2 Management of Seminoma (Stage I to Metastatic) 9.3 Management of Non-Seminoma (Stage I to Metastatic) 9.4 Penile Cancer: Staging, Organ-Sparing & Lymphadenectomy

10 Chapter 10: Benign Prostatic Hyperplasia & Lower Urinary Tract Symptoms

10.1 BPH Pathophysiology, Natural History & Clinical Evaluation 10.2 Medical Management of Male LUTS / BPO 10.3 Interventional & Surgical Management of BPO

11 Chapter 11: Functional Urology, Incontinence & Neuro-Urology

11.1 Urinary Incontinence in Men and Women, Fistulae & Urethral Diverticula 11.2 Overactive Bladder, Bladder Pain Syndrome & Pelvic Organ Prolapse 11.3 Neurogenic Lower Urinary Tract Dysfunction (NLUTD) 11.4 Urodynamic Studies: Indications, Technique & Interpretation

12 Chapter 12: Urolithiasis: Evaluation & Medical Management

12.1 Stone Pathophysiology & Risk Factors 12.2 Metabolic Evaluation & Dietary/Medical Stone Prevention 12.3 Acute Ureteric Colic & Medical Expulsive Therapy

13 Chapter 13: Endourology & Interventional Stone Management

13.1 Shock Wave Lithotripsy (SWL) 13.2 Ureteroscopy (URS) & Retrograde Intrarenal Surgery (RIRS) 13.3 Percutaneous Nephrolithotomy (PCNL) & Endourological Safety

14 Chapter 14: Infections, Andrology & Male Infertility

14.1 Localised & Systemic UTIs, Pyelonephritis, Urosepsis & Specific Infections 14.2 Prostatitis, Epididymo-Orchitis & Fournier Gangrene 14.3 Male Infertility: Evaluation & Surgical Management 14.4 Erectile Dysfunction, Peyronie Disease, Priapism & Gender-Affirming Surgery

15 Chapter 15: Paediatric Urology, Trauma & Renal Transplantation

15.1 Cryptorchidism, Hypospadias & PUJO 15.2 Vesicoureteral Reflux, Posterior Urethral Valves & Nocturnal Enuresis 15.3 Genitourinary Trauma: Kidney, Bladder & Urethra 15.4 Renal Failure, Dialysis Indications & Renal Transplantation

1.3 Clinical Decision-Making & MCQ Strategy

Key Takeaways Explain This Topic AI

Clinical vignettes may require integration of history, examination, laboratory markers, imaging and histology; use the patient data actually provided.

A useful four-step study method is to read the lead-in, extract discriminatory findings, anticipate the appropriate clinical action and compare the answer choices.

Check answer choices for outdated pathways, unnecessary intervention, incorrect drug indications and wrong treatment sequencing; off-label use alone does not make a treatment inappropriate.

Match treatment to disease risk and patient fitness: active surveillance is standard for suitable low-risk prostate cancer, and partial nephrectomy is recommended for technically suitable T1 renal tumours.

Last updated: November 2026

Clinical Decision-Making & MCQ Strategy

Success on the FEBU Part 1 Written Examination demands far more than raw factual memorization of urological texts. The European Board of Urology (EBU) assesses knowledge across the full spectrum of urology using Single-Best-Answer (SBA) multiple-choice questions. Clinical practice questions help candidates synthesise information, prioritise differential diagnoses and choose safe investigations or treatments under time pressure.

The following four-step method is a practical study technique. Use it to extract the relevant facts, check the clinical pathway and compare the answer choices; it is not a published EBU item-writing formula.

Information to Extract from a Clinical Vignette

When reading a clinical vignette, look for the following information when it is provided:

Patient Demographics and General Status :

Age and biological sex.

Functional performance status: World Health Organization (WHO) or Eastern Cooperative Oncology Group (ECOG) performance scale (crucial for systemic oncological therapy decisions, radical surgery versus radiotherapy, or surveillance).

Significant systemic comorbidities: Cardiovascular disease, active anticoagulation or antiplatelet therapy, chronic kidney disease (baseline eGFR), diabetes mellitus.

Presenting Symptoms and Chronology :

Chief complaint (e.g., painless gross hematuria, acute colicky flank pain, severe lower urinary tract symptoms, non-tender scrotal mass).

Onset, duration, and trajectory (acute vs. indolent).

Presence of constitutional red-flag symptoms: Unexplained weight loss, nocturnal fever, night sweats, bone pain.

Physical Examination Findings :

Digital rectal examination (DRE): Prostate volume estimate, asymmetry, induration, nodularity, or capsular extension (cT stage).

Abdominal and flank examination: Palpable abdominal mass, costovertebral angle tenderness.

Genital and scrotal examination: Transillumination, separability of mass from testis, epididymal tenderness, testicular position, Prehn sign.

Biochemical and Laboratory Parameters :

Serum markers: Prostate-Specific Antigen (PSA, including free/total ratio and kinetics), renal function (serum creatinine and eGFR), electrolytes, alkaline phosphatase.

Urinalysis and urine microscopy: Microscopic vs. macroscopic hematuria, leukocyturia, bacteriuria, urinary cytology.

Oncological serum tumor markers: Alpha-fetoprotein (AFP), human chorionic gonadotropin (beta-hCG), lactate dehydrogenase (LDH) in suspected germ cell tumors.

Diagnostic Imaging and Endoscopy :

Ultrasound findings: Renal parenchymal echogenicity, hydronephrosis grade, stone shadowing, post-void residual (PVR) volume.

Advanced cross-sectional imaging: Multiparametric MRI (mpMRI) with PI-RADS v2.1 scoring; contrast-enhanced multiphasic CT (corticomedullary, nephrographic, excretory phases); CT urogram.

Endoscopic findings: Rigid/flexible cystoscopy description (papillary, solid, sessile, multifocal; anatomical relation to ureteral orifices).

Histopathology and Pathological Staging :

Histological subtype and variant histology (e.g., urothelial carcinoma with squamous differentiation, clear cell vs. papillary vs. chromophobe RCC).

Grade and stage: International Society of Urological Pathology (ISUP) grade groups (1 to 5), Gleason score, tumour-specific TNM pathological staging, surgical margin status.

The 4-Step Question Breakdown Method

Under the time pressure of ~65 seconds per question, getting bogged down in extraneous vignette text causes cognitive fatigue and pacing failure. Candidates should employ the systematic 4-step question breakdown method : Step 1: Interrogative Lead-in ──► Step 2: Anchor Extraction ──► Step 3: Anticipation ──► Step 4: Distractor Elimination

Step 1: Read the Interrogative Lead-in First

Before reading the entire clinical narrative, look immediately at the final sentence (the lead-in) and skim the answer choices. This primes your working memory to filter the narrative for relevant data:

Is the question asking for the immediate next diagnostic step (e.g., urgent CT urogram vs. ultrasound), the immediate stabilization measure (e.g., emergency nephrostomy vs. antibiotic administration), or the definitive curative treatment (e.g., radical cystectomy vs. chemoradiation)?

Identifying the question type prevents answering what could be done eventually rather than what must be done next.

Step 2: Extract Key Clinical Anchors

Read the vignette actively, noting critical discriminating variables ("clinical anchors"):

Patient age and life expectancy : For low-risk prostate cancer, watchful waiting is standard when life expectancy is below 10 years; active surveillance is standard for a suitable healthy patient with life expectancy above 10 years.

Infection in the setting of obstruction : Flank pain + calculus + fever > 38.5 ∘ C >38.5^\circ\text{C} > 38. 5 ∘ C transforms elective stone management into a urological emergency requiring immediate decompression.

Biomarker elevation : Confirmed significantly elevated AFP unexplained by another cause in a tumour reported as pure seminoma suggests non-seminomatous elements; obtain expert pathology review and manage as NSGCT. Assess modest stable elevations before treatment.

Step 3: Anticipate the Guideline Recommendation (Unprompted Mental Solution)

Before scrutinizing the options, mentally formulate the gold-standard recommendation dictated by the EAU Guidelines. Formulating an unprompted answer shields you from being swayed by attractively phrased distractors.

Step 4: Eliminate Distractors and Confirm the Single Best Answer

Scan the options to find your predicted answer. If your predicted response is present, verify that none of the clinical anchors introduce a contraindication. If your predicted response is absent, systematically eliminate distractors by checking for clinical errors.

Recognizing Common Clinical Errors in Answer Choices

Review answer choices for recognisable errors in diagnosis, treatment selection or sequencing. The examples below illustrate clinical mistakes to avoid; they do not predict how EBU constructs individual distractors:

Trap 1: Obsolete Historical Practices

An outdated pathway can be a plausible distractor. Compare it with the current applicable recommendation:

Example : Performing systematic blind 12-core transrectal ultrasound (TRUS) biopsies without prior multiparametric MRI in biopsy-naive men suspected of prostate cancer. EAU strongly recommends MRI before biopsy for suspected organ-confined disease and recommends targeted biopsy with perilesional sampling for PI-RADS 4–5 lesions.

Example : Prescribing empirical fluoroquinolones for uncomplicated lower urinary tract infections or cystitis. European Medicines Agency (EMA) and EAU warnings have restricted fluoroquinolones due to long-lasting disabling adverse effects and high resistance rates.

Trap 2: Overtreatment and Inappropriate Invasiveness

Check whether immediate intervention is indicated:

Example : Suggesting immediate percutaneous nephrolithotomy (PCNL) or ureteroscopy for an asymptomatic, non-obstructing 4 mm lower pole caliceal calculus. The guideline-concordant approach is active observation with periodic ultrasonography.

Example : Recommending radical nephrectomy for a healthy patient with a 3.2 cm exophytic cT1a polar renal cortical mass with normal contralateral renal function. The EAU standard of care is nephron-sparing surgery (partial nephrectomy).

Trap 3: Premature or Incorrect Sequencing of Interventions

When several interventions are needed, distinguish immediate stabilisation and source control from later definitive treatment:

Example : In acute infected obstructive urolithiasis with sepsis, distractors will offer immediate ureteroscopic lithotripsy (URS) or shock wave lithotripsy (SWL). Manipulating or fragmenting a stone during active sepsis carries high mortality from septic shock; the only correct immediate intervention is emergent urinary decompression (ureteral stent or percutaneous nephrostomy) alongside intravenous antibiotics, delaying stone fragmentation until sepsis has completely resolved.

Example : Recommending radical orchiectomy via a scrotal approach or performing a transscrotal needle biopsy of a testicular mass. The mandatory oncological approach is inguinal exploration with early control of the spermatic cord.

Trap 4: Inappropriate Pharmacotherapy Regimens

Check the indication and contraindications of each proposed drug:

Example : Prescribing a 5-alpha reductase inhibitor (5-ARI) such as finasteride or dutasteride as monotherapy in a man with moderate LUTS but a prostate volume < 30 <30 < 30 mL. EAU recommends 5-ARIs for moderate-to-severe LUTS with increased progression risk, for example prostate volume > 40 >40 > 40 mL; an elevated PSA is not a separate mandatory prerequisite.

Example : Administering antimuscarinics to a patient with severe overactive bladder symptoms without first checking the post-void residual (PVR) volume, risking acute urinary retention in unrecognized high-residual states ( > 150 >150 > 150 – 200 200 200 mL).

Diagnostic and Decision Breakdown: High-Yield Clinical Scenarios

Clinical Presentation Key Discriminatory Anchors EAU Guideline First-Line Management Common Examiner Distractor Trap

Suspected Testicular Mass Painless firm intratesticular mass Bilateral testicular ultrasound and preoperative serum markers; suspected germ-cell malignancy is treated by radical inguinal orchiectomy Transscrotal biopsy or scrotal orchiectomy (violates lymphatic barriers)

Obstructive Pyelonephritis Ureteric calculus, fever > 38.5 ∘ C >38.5^\circ\text{C} > 38. 5 ∘ C , hypotension, leukocytosis Urgent decompression (Double-J stent or PCN) + IV antibiotics Immediate urgent URS stone extraction (induces bacteremia/urosepsis)

cT1a Renal Cell Carcinoma Incidental 2.8 cm solid contrast-enhancing renal mass, normal eGFR Partial nephrectomy (open, laparoscopic, or robot-assisted) Radical nephrectomy (causes avoidable renal function deterioration)

Low-Risk Prostate Cancer PSA 5.1 ng/mL, cT1c, ISUP Grade Group 1, < 3 <3 < 3 positive cores, life expectancy > 10 >10 > 10 years Active surveillance with regular PSA, DRE, and follow-up mpMRI/biopsies Immediate radical prostatectomy or immediate androgen deprivation therapy

Non-Muscle-Invasive Bladder Cancer 2 cm primary papillary bladder tumour, suspected low-grade Complete TURBT with single immediate post-op instillation of chemotherapy Immediate radical cystectomy or omission of post-operative instillation

High-Risk Upper Tract Urothelial Carcinoma High-grade cytology, 3 cm renal pelvis mass, invasive appearance Radical nephroureterectomy with excision of formal bladder cuff Endoscopic laser ablation (insufficient oncological clearance in high risk)

  • Official clinical references checked 6 November 2026
  • EAU prostate diagnostic and biopsy pathway
  • EAU prostate cancer guideline: staging and low-risk management
  • EAU renal tumour treatment
  • EAU stones: observation and infected obstruction
  • EAU male LUTS pharmacotherapy
  • EAU testicular cancer diagnosis
  • EAU high-risk UTUC management
  • EAU NMIBC treatment
  • EAU cystitis and antimicrobial restrictions